These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. Myocardial fibrosis and the effect of primary prophylactic defibrillator implantation in patients with non-ischemic systolic heart failure-DANISH-MRI. Elming MB; Hammer-Hansen S; Voges I; Nyktari E; Raja AA; Svendsen JH; Pehrson S; Signorovitch J; Køber L; Prasad SK; Thune JJ Am Heart J; 2020 Mar; 221():165-176. PubMed ID: 31955812 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction. Rørth R; Dewan P; Kristensen SL; Jhund PS; Petrie MC; Køber L; McMurray JJV Clin Res Cardiol; 2019 Aug; 108(8):868-877. PubMed ID: 30689020 [TBL] [Abstract][Full Text] [Related]
18. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Packer DL; Prutkin JM; Hellkamp AS; Mitchell LB; Bernstein RC; Wood F; Boehmer JP; Carlson MD; Frantz RP; McNulty SE; Rogers JG; Anderson J; Johnson GW; Walsh MN; Poole JE; Mark DB; Lee KL; Bardy GH Circulation; 2009 Dec; 120(22):2170-6. PubMed ID: 19917887 [TBL] [Abstract][Full Text] [Related]
19. Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial. Adabag S; Patton KK; Buxton AE; Rector TS; Ensrud KE; Vakil K; Levy WC; Poole JE JAMA Cardiol; 2017 Jul; 2(7):767-774. PubMed ID: 28724134 [TBL] [Abstract][Full Text] [Related]